tbuckley/cabot-search huggingface dataset:
Highlights
Journal: JAMA Internal Medicine (2014)

Obesity and Myocardial Infarction and Ischemic Heart Disease 15Overweight and obesity likely cause ischemic heart disease (IHD); however, whether coexisting metabolic syndrome is a necessary condition is unknown.Thomsen and Nordestgaard tested this hypothesis in 71 527 individuals from the Copenhagen General Population Study.During a median of 4 years of follow-up, they recorded 634 incident myocardial infarction and 1781 incident IHD events, finding that overweight and obesity were associated with increased risk of myocardial infarction and IHD independent of the presence or absence of metabolic syndrome.Jackson and Stampfer set the findings in context for clinicians and patients in an Invited Commentary. Invited Commentary 23 Risk Factor Management After Acute Coronary Syndrome 40Lifestyle changes after acute coronary syndrome reduce cardiovascular risk but are difficult for patients to achieve.In a 2-arm, parallel-group, multicenter randomized clinical trial, Cohen and coauthors sought to determine whether a nurse/dietician-led cardiovascular risk factor education program would improve risk factor reduction over the longer term after an acute coronary syndrome.They found no significant difference between the groups at 12 months for the primary outcome (smoking cessation, physical activity ≥3 hours per week, ≥5% reduction in waist circumference, or ≥4% reduction in weight).In an Invited Commentary, Fihn discusses cardiovascular risk factor interventions in the context of health care reform.
Ophthalmology
Authors: Frederick C. Blodi
Journal: JAMA (1979)

As both a medical and surgical specialty, ophthalmology has continued to advance. From an organizational point of view, the most notable event of the past year was the incorporation of a new and independent American Academy of Ophthalmology. The new organization is certain to become the rallying point of ophthalmologists and ophthalmic endeavors. Clinically, the year was marked by continued work on diabetic retinopathy, new findings that may affect the treatment of choroidal melanomas, new instrumentation for counting corneal endothelial cells, another method for measuring vision, and a new method for the treatment of malignant lid tumors. <h3>Diabetic Retinopathy</h3> Last year we reported the first results of the diabetic retinopathy collaborative study organized by the National Eye Institute. This study is being continued, and the indications for treatment have been refined. Certain risk factors (including retinal hemorrhages, neuvascularization of the disk, and neovascularization elsewhere) have been isolated and delineated. What
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): A pilot study from the GELA
Authors: R. Delarue, C. Haioun, P. Brice, A. Delmer, V. Ribrag, A. Van Hoof, O. Casasnovas, H. Tilly, G. Salles, O. Hermine
Journal: Journal of Clinical Oncology (2004)

6529
Promoting children's home safety
Authors: A. F Colver
Journal: BMJ (1982)

<h3>Objectives</h3> To examine clinical doctoral students’ demographic and training characteristics, career intentions, career preparedness and what influences them as they plan their future careers. <h3>Design and setting</h3> Online cross-sectional census surveys at two research-intensive medical schools in England in 2015–2016. <h3>Participants</h3> All medically qualified PhD students (N=523) enrolled at the University of Oxford and University College London were invited to participate. We report on data from 320 participants (54% male and 44% female), who were representative by gender of the invited population. <h3>Main outcome measures</h3> Career intentions. <h3>Results</h3> Respondents were mainly in specialty training, including close to training completion (25%, n=80), and 18% (n=57) had completed training. Half (50%, n=159) intended to pursue a clinical academic career (CAC) and 62% (n=198) were at least moderately likely to seek a clinical lectureship (CL). However, 51% (n=163) had little or no knowledge about CL posts. Those wanting a CAC tended to have the most predoctoral medical research experience (χ<sup>2</sup> (2, N=305)=22.19, p=0.0005). Key reasons cited for not pursuing a CAC were the small number of senior academic appointments available, the difficulty of obtaining research grants and work-life balance. <h3>Conclusions</h3> Findings suggest that urging predoctoral clinicians to gain varied research experience while ensuring availability of opportunities, and introducing more flexible recruitment criteria for CL appointments, would foster CACs. As CL posts are often only open to those still in training, the many postdoctoral clinicians who have completed training, or nearly done so, do not currently gain the opportunity the post offers to develop as independent researchers. Better opportunities should be accompanied by enhanced career support for clinical doctoral students (eg, to increase knowledge of CLs). Finally, ways to increase the number of senior clinical academic appointments should be explored since their lack seems to significantly influence career decisions.
Outbreak of Viral Gastroenteritis— Pennsylvania and Delaware
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AASLD abstract reviewers
Journal: Hepatology (2003)

COMMENTARY ON: Des-gamma-carboxy Prothrombin and Alpha fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group. Reprinted fromGastroenterology. 2009 Oct 20 [Epub ahead of print], with permission from Elsevier. Abstract: Background & Aims. The outcome of patients with hepatocellular carcinoma (HCC) remains poor because of late diagnosis. The aim of this study was to compare the accuracy of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) in the early diagnosis of HCC. Methods: Among 1031 patients randomized in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) Trial, a nested case-control study of 39 HCC cases (24 early stage) and 77 matched controls was conducted to compare the performance of AFP and DCP. Testing was performed on sera from 12 months prior (month-12) to the time of HCC diagnosis (month 0). Results: The sensitivity and specificity of DCP at month 0 was 74% and 86%, respectively, at a cut-off of 40 mAU/ml and 43% and 100%, respectively, at a cutoff of 150 mAU/ml. The sensitivity and specificity of AFP at month 0 was 61% and 81% at a cutoff of 20 ng/ml and 22% and 100% at a cutoff of 200 ng/ml. At month-12, the sensitivity and specificity at the low cutoff was 43% and 94%, respectively, for DCP and 47% and 75%, respectively, for AFP. Combining both markers increased the sensitivity to 91% at month 0 and 73% at month 12, but the specificity decreased to 74% and 71%, respectively. Diagnosis of early HCC was triggered by surveillance ultrasound in 14, doubling of AFP in 5, and combination of tests in 5 patients. Conclusions: Biomarkers are needed to complement ultrasound in the detection of early HCC, but neither DCP nor AFP is optimal.
Potential of Curcumin As A Multifunctional Agent to Combat Wilson Disease
Authors: Peter V. E. van den Berghe, Roderick H. J. Houwen, Leo W. J. Klomp
Journal: Hepatology (2010)

We thank Dr. Ji and Dr. Shen for mentioning other potential beneficial effects of curcumin on Wilson disease in addition to the improvement in the membrane expression of mutated copper-transporting adenosine triphosphatase (ATPase) ATP7B proteins that we described.1 Indeed, curcumin has drawn considerable attention recently as an agent with a broad range of properties that might be useful in liver diseases.2 The suggestion by Ji and Shen to conduct rigorous trials of curcumin in Wilson disease therefore seems timely. Nevertheless, some restraint seems appropriate. Even for decoppering agents that have proven effectiveness, such as D-penicillamine, zinc, and trientine, prospective, blinded, randomized clinical trials are lacking.3 As Wilson disease is rare, with an incidence of approximately 1:50,000, any prospective trial will face considerable organizational difficulties. Therefore, when trials are being developed, it seems proper to give priority to improving the evidence for established decoppering agents. We would therefore suggest that the potential of curcumin in Wilson disease should first be explored further in vitro. If it is proven effective, several animal models are available for both Wilson disease and other genetic diseases that cause copper overload (reviewed by Vonk et al.4), and they can subsequently be used to test the potential of curcumin to ameliorate or treat liver disease due to copper overload in vivo. Only when these results are clearly positive should human testing be considered. Dr. Peter V. E. van den Berghe M.D.* , Dr. Roderick H. J. Houwen M.D. , Dr. Leo W. J. Klomp M.D.* , * Departments of Metabolic and Endocrine Diseases, Metabolic Pediatric Gastroenterology, University Medical Center Utrecht, Utrecht, the Netherlands, Netherlands Metabolomics Center, Utrecht, the Netherlands.
Prolonged suppression of cough after inhalation of lidocaine in a patient with sarcoid
Authors: R. V. Sanders
Journal: JAMA (1984)

CHRONIC persistent cough can present both difficult diagnostic and therapeutic problems. Recent studies have primarily addressed the diagnostic evaluation of chronic cough, and these studies suggest that adequate treatment of the cause is highly effective in suppressing the cough.<sup>1,2</sup>In some patients, however, chronic cough may be caused by pulmonary disease that is unresponsive to therapy. Indeed, chronic cough may be more disabling than any other pulmonary symptom, such as dyspnea, and suppression of the cough then becomes a major therapeutic goal. We describe a patient with sarcoid with disabling cough who had an inadequate response to codeine, but who has had prolonged suppression of his cough after inhalation of nebulized lidocaine. <h3>Report of a Case</h3> A 34-year-old man was diagnosed as having pulmonary sarcoid in 1976 by chest roentgenogram and clinical course, confirmed in 1978 by mediastinal lymph node biopsy specimen showing noncaseating granulomata. He has taken prednisone
CHOLANGIOGRAPHY
Authors: P G KEIL, G J HEGSTROM, S J ZOECKLER
Journal: Annals of Internal Medicine (1953)

Article1 September 1953CHOLANGIOGRAPHYPHILIP G. KEIL, M.D., GEORGE J. HEGSTROM, M.D., SAMUEL J. ZOECKLER, M.D.PHILIP G. KEIL, M.D.Search for more papers by this author, GEORGE J. HEGSTROM, M.D.Search for more papers by this author, SAMUEL J. ZOECKLER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-39-3-479 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWhen most indicated, oral cholecystography is least reliable. It is most reliable when the biliary system is normal, and least reliable in the presence of disease. Visualization usually fails when this examination is most indicated—in the differential diagnosis of intrahepatic and extrahepatic obstruction. The cystic and common ducts are rarely visualized sufficiently for diagnosis, even when opacification of the gall-bladder is optimal. Another means of opacifying the gall-bladder and ducts which does not entail laparotomy is desirable.Added experience with cholangiography performed during peritoneoscopy reaffirms the value of this procedure in disease of the biliary system. There is little written...Bibliography1. Lee WY(a) : La peritoneoscopia, J. Internat. Coll. Surgeons 4: 511, 1941; (b) Evaluation of peritoneoscopy in intra-abdominal diagnosis, Rev. Gastroenterol. 9: 133, 1942. Google Scholar2. Hodges FJ: The gastro-intestinal tract, 1944, The Year Book Publishers, Inc., Chicago, p. 184. Google Scholar3. RoyerSolari HAV: Cholangiography performed with the help of peritoneoscopy, Gastroenterology 8: 586, 1947. MedlineGoogle Scholar4. RoyerMasureKohan MPS: Biliary dyskinesia studied by means of the "peritoneoscopic cholangiography," Gastroenterology 16: 83, 1950. CrossrefMedlineGoogle Scholar5. KeilLandis PGSN: Peritoneoscopic cholangiography, Arch. Int. Med. 88: 36, 1951. CrossrefGoogle Scholar6. JarvinenPaltia KAVE: Differential diagnosis of hepatitis and liver cirrhosis by means of cholecystography, Am. J. Digest. Dis. 19: 244, 1952. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Des Moines, Iowa*Received for publication March 9, 1953.From the Department of Internal Medicine, Veterans Administration Hospital, Des Moines, Iowa.Sponsored by the Veterans Administration with the approval of the Chief Medical Director. Statements and conclusions by the authors are a result of their own study and do not necessarily reflect the opinion or policy of the Veterans Administration. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPeritoneoscopy—A RevaluationDie laparoskopische Cholangiographie 1 September 1953Volume 39, Issue 3Page: 479-483KeywordsBiliary systemHospital medicineLaparoscopyLaparotomy ePublished: 1 December 2008 Issue Published: 1 September 1953 PDF downloadLoading ...
Excretion of 4-Amino-5-Imidazolecarboxamide by Mental Patients
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prospective assessment of circulating endothelial cells (CECs) as early markers of clear cell renal cell carcinoma (CCRCC) progression in first-line setting: The Circles study (SOGUG 2011-01).
Authors: Victor Oyarvides, Daniel Castellano, Luis Leon Mateos, Emilio Esteban, Laura Basterretxea, Aranzazu Gonzalez del Alba, Jose Angel Arranz Arija, Maria Jose Mendez, Francisco Javier Garcia Del Muro, Miguel Angel Climent, Juan Antonio Virizuela, Susana Hernando POLO, Jesus Garcia-Donas
Journal: Journal of Clinical Oncology (2013)

436 Background: Angiogenesis inhibitors have become a cornerstone in the management of clear cell renal cell carcinoma (CCRCC). Since circulating endothelial cells (CECs) counts have been proposed as surrogate biomarkers of angiogenesis, they could potentially be used to assess the activity of such drugs. Methods: An observational prospective study is being performed in 11 institutions members of the SOGUG group. Patients with confirmed CCRCC on first-line treatment who have not progressed after 3 months of therapy are considered eligible. CECs (CD 105+,CD 45-, DAPI + cells assessed by the Cell Search system), are determined every 6 weeks for 15 months or radiological tumor progression. Results: Up to 64 of the 75 scheduled patients have already been recruited. Mean age was 64 years, 73% were men and 27% women. Distribution upon MSKCC risk cathegories was: good 30%, intermediate 58%, poor 3% and not available (N/A) 9%. 57 (90%) patients received sunitinib, 3 (5%) pazopanib, 1 (2%) temsirolimus and was N/A in 3 (5%). The CECs counts were determined in 60 patients. At baseline median was 47 cells/4 ml (range 4-480). When comparing patients who experienced tumor progression while on study (11 cases) with patients who did not (28 CECs/4 ml vs. 73 CECs/4ml respectively), a significant difference was found (p = 0.002, t-student). Several exploratory analysis regarding concomitant conditions and patients and tumor characteristics showed that cases with heavily treated hypertension (8 in 60 patients) had lower baseline CECs counts, though without statistical significance (p = 0.068, t-student). Conclusions: Our data point to a different behaviour of CECs counts among CCRCC patients tretated with anitangiogenic drugs that could lead to identify specific subpopulations. Mature results will be presented at the meeting.
Management of Myasthenia Gravis
Authors: Robert S. Schwab
Journal: New England Journal of Medicine (1963)

(Concluded) *A sustained-release form of pyridostigmine bromide (Mestinon Timespan) has been in use since 1956. This is a scored, slowly-absorbable tablet containing 180 mg. of pyridostigmine bromide or the equivalent of 3 of the regular tablets of the medication. The effect of the medication is sustained for six to eight hours, and it is therefore very useful to take at bedtime to keep the patient's antimyasthenic medication effective during the sleeping hours, and to avoid the necessity of waking up in the middle of the night to take medicine. Since the effects do last for six to eight hours it . . .
Herpes Zoster
Authors: J. Kay
Journal: BMJ (1956)

Previously, we showed that CD137 ligand (CD137L; AKA 4-1BBL) contributes to the development of behavioral hypersensitivity and functional recovery in mice following peripheral nerve injury-induced neuropathic pain. Mice that lack CD137L showed reduced sensory sensitivity and faster functional recovery. Here, we sought to further investigate the potential involvement of lumbar spinal cord microglial responses in CD137L-mediated behavioral changes following sciatic nerve crush. Lumbar spinal cord microglia were isolated from both wild type B6 and CD137L knockout (KO)_B6 mice via positive selection based on CD11b expression using magnetic beads at days 0 (naïve), 3, 7, 14, 28 and 56 following sciatic nerve crush or sham surgery. Following RNA extraction, qRT-PCR were performed to examine cytokine/chemokine expression in isolated microglia. Our preliminary results suggest that male mice had more measurable cytokine/chemokine responses than female mice. Despite that many cytokines are below the detection levels, we were able to observe increased expression of several chemokines, CCL2, CCL3, CCL4 and CCL5 in microglia from CD137L KO mice, which appeared to peak early following injury (Days 3–14) than that in microglia isolated from WT mice. Future study will determine the involvement of microglial chemokine responses in CD137L mediated sensory hypersensitivity and delayed functional recovery following peripheral nerve injury.
Spontaneous Tumors in SENCAR Mice
Authors: Susan Melchionne, Irving Seidman, Benjamin L. Van Duuren
Journal: Environmental Health Perspectives (1986)

A total of 305 female and 36 male SENCAR mice in six different groups were observed for 540 to 875 days for tumors as well as nonneoplastic lesions. Three of these groups were observed for their lifespans. The 123 females and 36 males, observed for their lifespans (800 to 875 days) showed median survival times ranging from 730 to 745 days. The average peak body weights were 42.4 g for females and 50.0 g for males. In the animals observed for their lifespans, the total tumor incidence was 65.6% for females and 69.4% for males. Both sexes showed a high incidence of papillary tumors of the lung, 16 to 39%, which was independent of aging. Females showed a 5.1 to 21.0% incidence of mammary tumors, which increased with age. Males showed a high incidence of hyperplastic nodules of the liver, i.e., 12 of 36 animals. Other frequently occurring tumors were leukemia and papillomas of the forestomach.
Toxicity of Polybrominated Biphenyls (PBBs) in Domestic and Laboratory Animals
Authors: Terri Damstra, William Jurgelski, Herbert S. Posner, Velimir B. Vouk, N. Jean Bernheim, Janet Guthrie, Michael Luster, Hans L. Falk
Journal: Environmental Health Perspectives (1982)

The composition, environmental fate, and effects of the polybrominated biphenyls (Firemaster BP-6 or FF-1) involved in the accidental contamination of cattle feed in Michigan in 1973 are reviewed. Toxic effects referred to in this report are limited to those occurring in domestic and laboratory animals and include general toxicity, neurobehavioral toxicity, immunotoxicity, reproductive toxicity, mutagenicity and carcinogenicity. The absorption, distribution, biotransformation and elimination of these polybrominated biphenyls are discussed along with the interactions with other chemicals and drugs.
The Psychiatrist and the Normal Adolescent
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)
Authors: L. Heesen, K. Frenzel, S. Bolte, V. Bukur, M. Diken, E. Derhovanessian, S. Kreiter, A. Kuhn, K. Kühlcke, M. Löwer, H. Lindman, S. Pascolo, M. Schmidt, A. Schneeweiss, T. Sjöblom, K. Thielemans, L. Zitvogel, Ö Türeci, U. Sahin
Journal: Annals of Oncology (2018)